NEW YORK (GenomeWeb) – Speakers at the annual meeting of the American Society for Clinical Oncology, which wrapped up earlier this week, largely agreed that molecular testing and precision treatment have reached a new maturity in the practice of cancer medicine.

However, as the landscape of clinical and commercial genomic tests become more and more intricate, navigating this new world continues to challenge clinicians, some of whom discussed these practicalities at an ASCO session on implementing precision medicine.